Chief Business Officer

Tapan Maniar

Tapan is a Co-Founder and Chief Business Officer at Verdiva. He brings over 15 years of leadership experience in life sciences, spanning corporate and business development, strategy, operations, and equity investing. Most recently, Tapan served as Chief Business Officer and a founding team member at Aiolos Bio, where he led international licensing negotiations and played a pivotal role in the company’s acquisition by GSK in 2024.

Prior to Aiolos, Tapan was a Principal investment professional at Bain Capital Life Sciences, where he contributed to deal sourcing, evaluation, and execution, while also providing post-investment support to biotechs. He played a pivotal role in leading investments in ADARx, Aiolos, Areteia, Emalex, and Rivus Pharma, while also serving as a Board Observer for Rivus and Emalex.

Previously, Tapan was Head of Business Development at Genentech, focusing on technology platforms and asset-based transactions. He established and guided a high-performing team to identify and execute strategic partnerships, acquisitions, and licensing deals. Prior to Genentech, Tapan was a management consultant in McKinsey & Company’s healthcare practice.

Tapan holds a PhD in Neuroscience from The Rockefeller University and a bachelor’s degree in Biology from Bard College.